SBIR Commercialization Plans After Reauthorization: What Agencies Want in 2026

The SBIR reauthorization did not just extend the program — it restructured incentives around commercialization in ways that will change how proposals are scored for years. Strategic Breakthrough Awards, the marquee new mechanism, require 100 percent matching funds from non-federal sources. That requirement signals a shift that goes beyond one award type: across all 11 participating agencies, the commercialization plan is no longer a formality tucked at the end of your proposal. It is becoming a primary evaluation criterion.

Companies that treat the commercialization section as an afterthought — vague market descriptions, aspirational revenue curves, no customer evidence — will feel the impact in their scores. Here is what agencies actually want in 2026 and how to deliver it.

The Post-Reauthorization Commercialization Landscape

Before reauthorization, commercialization was weighted unevenly across agencies. NSF scored it heavily, DoD cared about transition to programs of record, and some civilian agencies barely looked at it. The reauthorization harmonizes that emphasis by tying program metrics — and agency reporting requirements — more directly to commercialization outcomes.

The Strategic Breakthrough Award pathway makes this concrete. Companies competing for these larger awards must demonstrate that private capital is already committed alongside the SBIR funding. Even for standard Phase I and Phase II proposals, the signal is clear: reviewers are being told to take commercialization more seriously.

For companies building their first SBIR proposal, the SBIR Complete Application Guide covers the full proposal structure, including where the commercialization plan fits in each agency's template.

This does not mean that every Phase I proposal needs a venture-backed commercialization strategy. It means that the plan must be specific, evidence-based, and connected to a realistic path from R&D to revenue. The bar has moved from "show us you have thought about markets" to "show us you have talked to customers."

Six Elements Every Commercialization Plan Needs

Regardless of agency, strong commercialization plans share six components that reviewers look for on a first read.

Market size with credible sources. Total addressable market (TAM), serviceable addressable market (SAM), and serviceable obtainable market (SOM) — with citations. Reviewers flag market estimates that come without attribution. Use published market research, industry association data, or government procurement databases. A $50 billion TAM is meaningless without a credible path to your first $5 million in revenue.

Competitive landscape analysis. Name your competitors. Explain what they offer, where they fall short, and why your technology is differentiated. Reviewers are scientists and engineers — they respect honest competitive positioning over marketing claims. Acknowledging a strong competitor and explaining your specific advantage is more persuasive than pretending the market is wide open.

Customer validation evidence. Letters of intent, pilot agreements, beta testers, or documented conversations with potential buyers. This is the element that separates competitive proposals from the pack. A single letter from a potential customer stating interest in your technology carries more weight than ten pages of market analysis.

Intellectual property strategy. Patents filed, patents pending, trade secrets, and licensing approach. Agencies want to know that their SBIR investment will not be easily replicated by a larger competitor. If your IP position is early-stage, describe your filing timeline and what you plan to protect.

Go-to-market timeline. A concrete plan showing how you get from Phase II completion to first revenue. Include milestones: regulatory approvals, manufacturing scale-up, distribution agreements, sales hires. The timeline should be realistic — reviewers have seen enough proposals to know when a plan is aspirational versus grounded.

Revenue projections. Three-to-five-year revenue forecast with assumptions stated. Reviewers do not expect precision, but they do expect internal consistency. If your market analysis says the addressable market is $200 million and your five-year projection shows $500,000 in revenue, explain the disconnect. If your projection shows $50 million, show the customer pipeline that supports it.

Agency-Specific Emphasis: Where the Weight Falls

Not all agencies score commercialization identically, and understanding the differences helps you calibrate your plan.

NSF places the heaviest weight on commercialization among all SBIR agencies. The Broader Impacts criterion explicitly includes commercial potential, and NSF I-Corps training is often referenced as a benchmark for customer discovery rigor. If you are applying to NSF, your commercialization plan should reflect I-Corps methodology — customer interviews, pivot history, and validated hypotheses.

DoD cares most about the transition pathway. Commercial market potential matters, but DoD reviewers want to see how your technology transitions to a program of record, a prime contractor supply chain, or an operational unit. Name the specific DoD program, platform, or system your technology supports. A letter from a program manager or prime contractor carries exceptional weight.

NIH evaluates commercialization through the lens of clinical and market pathways. For therapeutics, reviewers want to see your regulatory strategy (FDA pathway, clinical trial plan). For diagnostics and devices, they want reimbursement strategy and distribution channels. NIH commercialization plans must address both the scientific pathway to a product and the business pathway to revenue.

DOE, USDA, and civilian agencies vary in emphasis but generally look for evidence that the technology has applications beyond the specific research problem. DOE in particular values dual-use potential — technologies that serve both government and commercial energy markets.

For companies that have previously written NIH-specific commercialization plans, the NIH SBIR commercialization strategy guide covers the clinical pathway details that NIH reviewers prioritize.

Common Weaknesses That Kill Scores

Reviewing hundreds of SBIR commercialization plans reveals the same failure modes repeatedly.

Vague market descriptions that rely on broad industry categories without drilling into the specific segment your technology serves. Saying your product addresses the "$4.3 trillion healthcare market" tells reviewers nothing about your actual commercial opportunity.

No customer evidence beyond desk research. Market reports and industry analyses are table stakes. Reviewers want to see that you have spoken to actual potential buyers and that those conversations informed your plan. Even five documented customer discovery interviews outweigh a polished market analysis.

Unrealistic revenue projections that show hockey-stick growth without explaining the mechanism. If your plan projects $20 million in year three but you have no sales team, no distribution partner, and no manufacturing capacity, reviewers will discount the entire section.

Ignoring the competitive response. Your technology may be superior today, but what happens when a well-funded competitor sees your SBIR-funded innovation? Reviewers want to see that you have considered defensibility — through IP, speed to market, regulatory head starts, or customer lock-in.

Connecting Commercialization to the Strategic Breakthrough Pathway

The reauthorization's Strategic Breakthrough Awards create a direct link between your commercialization plan and your eligibility for the program's largest awards. Companies that demonstrate strong commercial traction — customer commitments, matching investment, revenue from prior SBIR work — position themselves for this pathway.

Even if you are not applying for a Strategic Breakthrough Award today, structuring your commercialization plan as if you might pursue one later signals sophistication to reviewers. It shows that you see SBIR as an on-ramp to a commercial business, not as a grant-funded research program.

Companies looking for SBIR opportunities across agencies can browse current solicitations on Granted's SBIR page, which covers eligibility, timelines, and agency-specific guidance.

Building a commercialization plan that holds up to post-reauthorization scrutiny takes real customer evidence and honest market analysis — Granted can help you structure that plan around the evidence you have and identify the gaps before reviewers do.